Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen

International Journal of Dermatology

Volumn 47, Issue 8, 2008, Pages 800-805

  Borska, Lenka ^a,b   Andrys, Ctirad ^a   Krejsek, Jan ^a   Hamakova, Kvetoslava ^a   Kremlacek, Jan ^a   Ettler, Karel ^a   Fiala, Zdenek ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

COAL TAR; INTERLEUKIN 10; INTERLEUKIN 12; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CZECH REPUBLIC; DESQUAMATION; DISEASE ACTIVITY; ERYTHEMA; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUESTIONNAIRE; RADIATION DOSE; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COAL TAR; COMBINED MODALITY THERAPY; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; OINTMENTS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PSORIASIS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 48249088180     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03677.x     Document Type: Article

References (31)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
3. de Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Dermatol Ther 2004; 17: 341-349.
4. Shaker OG, Moustafa W, Essmat S, et al. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem 2006; 39: 119-125.
5. Anderson EJ, McGrath MA, Thalhamer T, et al. Interleukin-12 to interleukin "infinity": The rationale for future therapeutic cytokine targeting. Springer Semin Immunopathol 2006; 27: 425-442.
6. Tada Y, Asahina A, Takekoshi T, et al. Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin. Am J Dermatol 2006; 154: 1180-1183.
7. Szegedi A, Aleksza M, Gonda A, et al. Elevated rate of Thelper1 (Th1) lymphocytes and serum IFN-γ levels in psoriatic patients. Immunol Lett 2003; 86: 277-280.
8. Roussaki-Schulze AV, Kouskoukis C, Petinaki E, et al. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res 2005; 25: 169-173.
9. Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279.
10. Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003; 12: 309-313.
11. Asadullah K, Sabat R, Friedrich M, et al. Interleukin-10: An important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3: 185-192.
12. Sharma V, Kaur I, Kuma B. Calcipotriol versus coal tar: A prospective randomized study in stable plaque psoriasis. Int J Dermatol 2003; 42: 834-838.
13. Borska L, Fiala Z, Krejsek J, et al. Selected immunological changes in patients with Goeckerman's therapy: TNF-alpha, sE-selectin, sP-selectin, sICAM-1 and IL-8. Physiol Res 2006; 55: 699-706a.
14. Borska L, Fiala Z, Krejsek J, et al. Cytogenetic and immunological changes after dermal exposure to polycyclic aromatic hydrocarbons and UV radiation. Physiol Res 2006; 55: 317-323b.
15. Fiala Z, Borska L, Pastorkova A, et al. Genotoxic effect of Goeckerman regimen of psoriasis. Arch Dermatol Res 2006; 298: 243-251.
16. Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007; 298: 479-483.
17. Luster MI, Rosenthal GJ. Chemical agents and immune response. Environ Health Perspect 1993; 101: 219-226.
18. Burchiel SW, Luster MI. Signaling by environmental polycyclic aromatic hydrocarbons in human lymphocytes. Clin Immunol 2001; 98: 2-10.
19. Laupeze B, Amiot L, Sparfel L, et al. Polycyclic aromatic hydrocarbons affect functional differentiation and maturation of human monocyte-derived dendritic cells. J Immunol 2002; 168: 2652-2658.
20. Kim E, Kang BY, Kim TS. Inhibition of interleukin-12 production in mouse macrophages by hydroquinone, a reactive metabolite of benzene, via suppression of nuclear factor-kappaB binding activity. Immunol Lett 2005; 99: 24-29.
21. Katiyar SK. Interleukin-12 and photocarcinogenesis. Toxicol Appl Pharmacol 2007; 224: 220-227.
22. Schwarz A, Schwarz T. Molecular determinants of UV-induced immunosuppression. Exp Dermatol 2002; 11: 9-12.
23. McLoone P, Man I, Yule S, et al. Whole-body UVB (TL-01) or UVA-1 radiation does not alter the levels of immunomodulatory cytokines in the serum of human volunteers. Photodermatol Photoimmunol Photomed 2004; 20: 76-80.
24. Walters IB, Ozawa M, Cardinale I, et al. Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: Differential regulation of cytokines at the single-cell level. Arch Dermatol 2003; 139: 155-161.
25. Zhang LJ, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol 2006; 12: 1681-1685.
26. Moore KW, De Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
27. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: 67-80.
28. Numerof RP, Asadullah K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. Biodrugs 2006; 20: 93-103.
29. Pacheco KA, Tarkowski M, Sterritt C, et al. The influence of diesel exhaust particles on mononuclear phagocytic cell-derived cytokines: IL-10, TGF-beta and IL-1 beta. Clin Exp Immunol 2001; 126: 374-383.
30. Jones CD, Guckian M, el-Ghorr AA, et al. Effects of phototherapy on the production of cytokines by peripheral blood mononuclear cells and on systemic antibody responses in patients with psoriasis. Photodermatol Photoimmunol Photomed 1996; 12: 204-210.
31. Leon A, Nguyen A, Letsinger J, et al. An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: Review of the efficacy and safety of biologics and prebiologic options. Expert Opin Pharmacother 2007; 8: 617-632.